AstraZeneca, BMS Expand Development Of Diabetes Drug Dapagliflozin To Include Japan
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal is “natural progression” of two companies collaborations; dapagliflozin is currently in Phase II trials in Japan and Phase III in the U.S.
You may also be interested in...
Takeda’s Alogliptin Strategy: Treatment Options
With patent protection for its blockbuster insulin-resistance drug Actos (pioglitazone) set to expire in 2011, Takeda is testing its new Type 2 diabetes candidate, alogliptin, in several therapeutic settings to give physicians confidence the drug will fit into a variety of treatment plans
More Reform Eyed For Japan's OTC Deregulation
Japan's executive branch will urge the country's drug regulators to relax recently imposed limits on online sales of OTC products
More Reform Eyed For Japan's OTC Deregulation
Japan's executive branch will urge the country's drug regulators to relax recently imposed limits on online sales of OTC products